TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05259826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy sampling
Description: 1. Biopsies are homogenised in buffer and used for the determination of mucosal IgE and inflammatory parameters.~2. Biopsies are used to isolate organoids, stimulate them with blood cells and food antigens and to study gene and protein expression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy sampling
Description: 1. Biopsies are homogenised in buffer and used for the determination of mucosal IgE and inflammatory parameters.~2. Biopsies are used to isolate organoids, stimulate them with blood cells and food antigens and to study gene and protein expression.
Study: NCT05200273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK114
Description: AK114 administered by subcutaneous injection
Study: NCT06433167

Intervention type: OTHER
Intervention: Pedobarographic analysis
Description: During the pedobarographic analysis, the patient takes steps on the platform at a regular walking speed, with arms relaxed at the sides, following a natural gait. In static analysis, measurements are taken while the patient remains stationary on the platform with arms in a relaxed position beside the body. Five measurements are separately recorded for both feet during the phases of stepping, heel strike, and toe lift. These measurements capture the highest pressures on the back of the foot, the middle part of the foot, and the inner, middle, and lateral sides of the front of the foot, including the toes. The pressure, force, and pressure-time integral corresponding to each area are then used to determine how and for how long these areas are exposed to pressure.

Intervention type: OTHER
Intervention: Pedobarographic analysis
Description: During the pedobarographic analysis, the patient takes steps on the platform at a regular walking speed, with arms relaxed at the sides, following a natural gait. In static analysis, measurements are taken while the patient remains stationary on the platform with arms in a relaxed position beside the body. Five measurements are separately recorded for both feet during the phases of stepping, heel strike, and toe lift. These measurements capture the highest pressures on the back of the foot, the middle part of the foot, and the inner, middle, and lateral sides of the front of the foot, including the toes. The pressure, force, and pressure-time integral corresponding to each area are then used to determine how and for how long these areas are exposed to pressure.
Study: NCT05078593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
Study: NCT06522815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CART-I plus
Description: CART-I PLUS collects signals in two ways:~ECG: Utilizes the metal on the inner and outer sides as electrodes to detect subtle electrical changes resulting from the contraction and relaxation of the heart muscle.~PPG: Emits LED light into the blood vessels inside the finger and collects the signal reflected by the blood flow, thereby gathering data on the pulse and functional oxygen saturation (SpO2) of arterial hemoglobin.~In this clinical trial, PPG signals will be continuously collected during the polysomnography using the PPG method.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: In polysomnography, the following data are collected:~Electrocardiogram (ECG), Electroencephalogram (EEG), Electromyogram (EMG), Electrooculogram (EOG), Oxygen Saturation (SpO2) Respiratory Analysis, Body Position Monitoring
Study: NCT06185231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percussion Massage Group
Description: In addition progressive exercise program, The Percussion massage group will receive percussion massage therapy for a total of 5 minutes for each muscle group. The application will be done to the Quadriceps and Hamstring muscle groups before exercise. Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Group
Description: Conventional group undergo a progressive exercise program given as Phase-1, Phase-2, and Phase-3 for 6 weeks.~Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes.
Study: NCT05009953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome Injection
Description: Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome Injection
Description: Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, intravenously, over 60 min on days 1 of every 14-day cycle, 100mg/10mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle
Study: NCT04625699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 4 doses of Durvalumab 1500 mg IV Day 1, q28 days (For example, interventions involving drugs may include dosage form, dosage, frequency, and duration.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 2 doses of Tremelimumab 300 mg IV Day 1, q56 days
Study: NCT05857189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digitalized printed paper
Description: Patients will receive a newly formed digitalized printed paper inserted into eyeglasses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional drawing image
Description: Patients will receive eyeglasses that hold a traditional drawing image of the eye

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy controls
Description: Patients will include volunteering participants with un defected eye
Study: NCT05461170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NRTI
Description: NRTI given orally.
Study: NCT05020587

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Open pilot trial of a group therapy manual.
Description: Open pilot trial of a group therapy manual.
Study: NCT05072028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]DBPR108
Description: \[14C\]DBPR108, single dose of 100 mg (radioactivity of 150 µCi), oral
Study: NCT06270043

Intervention type: PROCEDURE
Intervention: Focal Therapy
Description: Focal ablation of prostate cancer using different modalities. These modalities include:~* Cryoablation or Cryotherapy~* Irreversible Electroporation - Nanoknife~* High Intensity Frequency Ultrasound - FocalOne~* Transurethral Ultrasound Ablation - TULSA - PRO
Study: NCT06172192

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core Strengthening
Description: 1. Warm up phase Following exercise would be performed in warm up. Jump rope, Cross jacks, Standing side crunch, Mountain climbers, Scissor skier, Criss cross crunches, Reverse lunge high kick, Inchworm, Hip circles, Bent over.~2. Core Strengthening:~   Abdominal bracing, Bracing with heel slides, Bracing with leg lifts, Bracing with bridging, Bracing in standing, Bracing with standing row exercise, Quadruped arm lifts with bracing, Quadruped leg lifts with bracing, Quadruped alternate arm and leg lifts with bracing , Oblique abdominals~3. Cool down phase: Following exercise would be performed for cood down: child pose, Ab stretch, cat cow stretch, hip stretch, oblique stretch, standing forward bend.~After performance of core strengthening protocol, group A will perform self-diaphragmatic breathing exercises while group B will perform resistive diaphragmatic breathing exercise.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Strengthening
Description: 1. Warm up phase Following exercise would be performed in warm up. Jump rope, Cross jacks, Standing side crunch, Mountain climbers, Scissor skier, Criss cross crunches, Reverse lunge high kick, Inchworm, Hip circles, Bent over.~2. Core Strengthening:~   Abdominal bracing, Bracing with heel slides, Bracing with leg lifts, Bracing with bridging, Bracing in standing, Bracing with standing row exercise, Quadruped arm lifts with bracing, Quadruped leg lifts with bracing, Quadruped alternate arm and leg lifts with bracing , Oblique abdominals~3. Cool down phase: Following exercise would be performed for cood down: child pose, Ab stretch, cat cow stretch, hip stretch, oblique stretch, standing forward bend.~After performance of core strengthening protocol, group A will perform self-diaphragmatic breathing exercises while group B will perform resistive diaphragmatic breathing exercise.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-Diaphragm breathing exercises
Description: Participants will place one hand on the chest and other on the abdomen, feeling the swelling of the stomach and the movement of the chest. It will be performed in supine position.~Supervised breathing exercises in two sets for 15 minutes with 5 minutes break between sets and 10 minutes rest after it will be performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistive-Diaphragm breathing exercises
Description: Participants will place one hand on the chest and another on the sand bag placed over abdomen. This sand bag weighing 3-5 Kgs will provide resistance to breathing. These exercises will be performed in supine position. We will adjust the weight of the sandbag as per individual's level of 11-13 of 'Rating of Perceived Exercise (RPE)'.~Supervised breathing exercises in two sets for 15 minutes with 5 minutes break between sets and 10 minutes rest after it will be performed
Study: NCT04790578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZoeInsights Application
Description: ZI is designed to promote PA behavior change and maintenance via self-monitoring of PA, symptoms, and other health data. Additional information for using ZI will be provided via a PDF-based user guide on installing and using the application, a live instructional webinar hosted by ZI developer Hanalytics Solutions, and access to continued support via email/telephone communication with study staff as well as Hanalytics Solutions. Reminders to complete self-monitoring tasks will be provided using daily push notifications scheduled according to participant preferences. Automatic graphs will be generated and displayed within the app to allow participants to visualize trends in physical activity, symptoms, and other health data. ZI can be accessed via a web browser on any device that is connected to the internet (e.g. computer, laptop, tablet, smartphone), or via a native android or iOS mobile application on a smartphone or tablet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EXCEL Exercise Class
Description: The group based remote exercise program is delivered twice a week over the Zoom application. Classes are one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretching. Each class is followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXCEL Exercise Class
Description: The group based remote exercise program is delivered twice a week over the Zoom application. Classes are one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretching. Each class is followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
Study: NCT06117696

Intervention type: OTHER
Intervention: Animated video
Description: delivery of written and oral information, supported by animated videos.
Study: NCT06446414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Move
Description: As described under study arm description
Study: NCT05626309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qizhu Yuling Prescription
Description: The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
Study: NCT05132127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sutimlimab
Description: Pharmaceutical form: solution for injection Route of administration: intravenous (IV)
Study: NCT05978206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone Decanoate
Description: Patients will receive nandrolone decanoate (1 ml, 50 mg/ml intramuscularly given per visit) or placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy Intervention
Description: The physiotherapeutic intervention includes the following components:~1. Strength training will include strength exercises 3 x a week x 30 min - load from 60% to 80% 1RM for individual muscle groups, - 10 repetitions of the exercise, - 1-3 series in 1 session (break between sessions 60 seconds).~2. Endurance training will include aerobic exercises (cycle ergometer, treadmill, general fitness exercises) 3 times a week x 30 minutes, load from 60% to 80% of maximum heart rate.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy Intervention
Description: The physiotherapeutic intervention includes the following components:~1. Strength training will include strength exercises 3 x a week x 30 min - load from 60% to 80% 1RM for individual muscle groups, - 10 repetitions of the exercise, - 1-3 series in 1 session (break between sessions 60 seconds).~2. Endurance training will include aerobic exercises (cycle ergometer, treadmill, general fitness exercises) 3 times a week x 30 minutes, load from 60% to 80% of maximum heart rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: An individual diet in terms of calorific value and the content of energy substrates - proteins, fats and carbohydrates, as well as other nutrients, in accordance with specific nutrition standards.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional Intervention
Description: An individual diet in terms of calorific value and the content of energy substrates - proteins, fats and carbohydrates, as well as other nutrients, in accordance with specific nutrition standards.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05183672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telecare consultation
Description: Using Zoom to communicate with patients

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Usual face-to-face consultation
Description: Face-to-face communication with patients
Study: NCT05060549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Participants will receive 6 weeks of cariprazine treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Participants will receive 6 weeks of cariprazine treatment
Study: NCT05871320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [99mTc]Tc-TECANT1
Description: only one arm - the administration of \[99mTC\]-Tc-TECANT1 in all patients included
Study: NCT05029908

Intervention type: DIAGNOSTIC_TEST
Intervention: Jaw Functional Limitation Scale
Description: DC/TMD Axis I TMD Pain Screener Questionnaire and TMD Symptom Questionnaire will be administered to the participants. To determine parafunctional habits and limitation of function, the DC/TMD Axis II assessment tools 'Jaw Functional Limitation Scale-8 (JFLS-8) and Oral Behavioral Checklist (OBC) will be applied. In addition, demographic data (age, gender, education level, occupation) will be questioned.
Study: NCT04958876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-104
Description: oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-104
Description: oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone immediate release oral capsules
Description: oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone immediate release oral capsules
Description: oral capsule once daily
Study: NCT05155670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WRL HX MCP
Description: WRL HX MCP is a non CE marked class IIa medical device designed for clinical application in hand rehabilitation; it consists in a cable-driven robotic MCP orthosis providing flexion-extension of the metacarpo-phalangeal joint. WRL HX MCP features and a series-elastic actuators (SEA) architecture for compliant actuation of MCP flexion-extension and a self-aligning mechanism to absorb human/robot joint axes misplacement. Exoskeleton module is mounted on a dorsal hand support and connected to its electronic box through wires.
Study: NCT05596253

Intervention type: PROCEDURE
Intervention: TIPS
Description: TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
Study: NCT05034159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Same as is described previously.
Study: NCT06104553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1912; R-Chemo
Description: SHR-A1912 combined with R-Chemo: SHR-A1912 + R-Chemo (Rituximab + Chemotherapy) (Phase 1b)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1912; R-Chemo
Description: SHR-A1912 combined with R-Chemo: SHR-A1912 (RP2D) + R-Chemo (Rituximab + Chemotherapy) (Phase 2)
Study: NCT05456204

Intervention type: DRUG
Group type: OTHER
Intervention: Pharmacological cardioversion with Refralon
Description: 1. the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~2. in the absence of effect (SR recovery did not occur), after 15 minutes,repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~3. in the absence of effect (SR recovery did not occur),after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~4. in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight.
Study: NCT06177288

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DEBIRI Combined With Chemotherapy and Bevacizumab
Description: After dissolving 100 mg of irinotecan in water for injection or 4ml of 5% glucose water.use 2mL of 70μm uniform particle size microspheres for loading and adsorption for 5minutes. Then mixed with non-plasma contrast agent to embolize the tumor feeding artery.
Study: NCT06123702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear extinction
Description: Extinction of conditioned fear response

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fear extinction
Description: Extinction of conditioned fear response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Cap/Tab
Description: 12 50-mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 placebo capsules
Study: NCT05902949

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Streching Group
Description: The Streching group will perform a conventional stretching exercise.
Study: NCT06436989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hot purified water
Description: Hot purified water,drink once a workday,almost 360mL.Buy from regular channels.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hot purified water
Description: Hot purified water,drink once a workday,almost 360mL.Buy from regular channels.